Prosthetic Vascular Conduits for Cardiovascular Structures
Vascular grafts for reconstructing and/or replacing damaged or diseased cardiovascular vessels that are formed from decellularized fetal small intestine. In some aspects, the vascular grafts include structural reinforcement means, such as a biodegradable polymeric braided structure, disposed proximate the outer surface
1 . A vascular graft for reconstructing and replacing damaged cardiovascular vessels, comprising:
a seamless tubular member comprising decellularized fetal small intestine, said tubular member having a first length, proximal and distal ends, an outer surface and a lumen that extends therethrough
said tubular member further comprising reinforcement means disposed proximate said tubular member outer surface.
2 . The vascular graft of claim 1 , wherein said tubular member further comprises at least one additional biologically active agent.
3 . The vascular graft of claim 2 , wherein said biologically active agent comprises a cell selected from the group consisting of a human embryonic stem cell, fetal cardiomyocyte, myofibroblast, and mesenchymal stem cell.
4 . The vascular graft of claim 2 , wherein said biologically active agent comprises a growth factor selected from the group consisting of a transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), fibroblast growth factor-2 (FGF-2), basic fibroblast growth factor (bFGF), and vascular epithelial growth factor (VEGF).
5 . The vascular graft of claim 1 , wherein said tubular member further comprises at least one pharmacological agent.
6 . The vascular graft of claim 5 , wherein said pharmacological agent comprises a statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.
7 . The vascular graft of claim 5 , wherein said pharmacological agent comprises an anti-arrhythmic agent selected from the group comprising quinidine, procainamide, disopyramide, lidocaine, phenytoin, mexiletine, flecainide, propafenone, moricizine, propranolol, esmolol, timolol, metoprolol, atenolol, amiodarone, sotalol, ibutilide, dofetilide, verapamil, diltiazem, adenosine and digoxin.
8 . The vascular graft of claim 5 , wherein said pharmacological agent comprises an anti-inflammatory.
9 . The vascular graft of claim 1 , wherein said tubular member further comprises at least one a biodegradable polymeric coating, said coating being disposed on at least a portion of said tubular member outer surface.
10 . The vascular graft of claim 9 , wherein said biodegradable polymeric coating comprises a coating formulation comprising polyhydroxyalkonates (PHAs), polylactides (PLLA) and polyglycolides (PLGA) and copolymers thereof, polyanhydrides, and mixtures thereof.
11 . The vascular graft of claim 1 , wherein said reinforcement means comprises a strand of reinforcing material that is wound around and disposed proximate said tubular member outer surface.
12 . The vascular graft of claim 11 , wherein said strand of reinforcing material comprises a biodegradable polymeric material.
13 . The vascular graft of claim 12 , wherein said biodegradable polymeric material is selected from the group consisting of a polyhydroxyalkonate (PHA), polylactide (PLLA) and polyglycolide (PLGA) and copolymers thereof, and a polyanhydride.
14 . The vascular graft of claim 11 , wherein said strand of reinforcing material comprises an extracellular matrix (ECM).
15 . The vascular graft of claim 11 , wherein said strand of reinforcing material comprises a biocompatible metal selected from the group consisting of stainless steel and Nitinol®.
16 . The vascular graft of claim 11 , wherein said strand of reinforcing material comprises magnesium.